Hannah Clarke

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

A decision is expected by the fourth quarter of 2026.

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.

This FAQ outlines key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.

A phase 1 study found topical sildenafil cream was linked with lower systemic exposure than oral sildenafil and was well tolerated in healthy men.

The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.

Higher saturated and animal fat intake was linked to increased mortality among men with nonmetastatic prostate cancer, according to a cohort study published in JAMA Network Open.

The FDA has provided an update on efforts to increase the supply of estradiol transdermal patches amid rising demand.

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

The FDA has granted clearance to a phase 1 trial of ADI-212, a PSMA-targeted, gene-edited, armored cell therapy candidate under development for mCRPC.

This FAQ outlines what the State of Men's Health Act would do, how a federal Office of Men’s Health could affect research and clinical care, and what urologists can do to support the effort.

A TRUMPET registry analysis found that initial disease presentation and family history were associated with survival outcomes in metastatic castration-resistant prostate cancer.

Datopotamab deruxtecan will be assessed alone and in combination with rilvegostomig as adjuvant treatment for patients with high-risk muscle-invasive urothelial carcinoma.

A national cohort study found that metabolic syndrome and its components were frequently documented within the first year of concurrent ADT and ARPI therapy for prostate cancer.

The phase 2 MODeFIRe-1 trial will evaluate investigational MRT-2359 plus apalutamide in AR-mutated metastatic castration-resistant prostate cancer.

Water vapor thermal therapy also provided greater QoL improvement vs combination pharmacotherapy while preserving sexual function.

The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.

The phase 2 RadiCaL trial found that adding radium-223 to cabozantinib did not improve skeletal event-free survival in metastatic renal cell carcinoma.

The phase 3 NRG-GU005 trial found SBRT improved bowel quality of life vs MH-IMRT but did not improve urinary outcomes or disease-free survival.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.